An Open-Label Phase 1b Study to Evaluate the Dose-Related Safety, Efficacy, and Pharmacokinetic Profile of Different Doses of QL-007 in Chronic Hepatitis B Patients
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2018
At a glance
- Drugs QL-007 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
- 12 Jul 2018 Planned End Date changed from 20 Aug 2018 to 30 Dec 2018.
- 12 Jul 2018 Planned primary completion date changed from 20 Mar 2018 to 30 Oct 2018.
- 12 Jul 2018 Status changed from not yet recruiting to recruiting.